European Commission launches strategy to drive innovation from lab to market

27 July 2008

The European Commission has adopted a Communication on a new industrial property rights strategy for the European Union. Together with the creation of an EU patent and integrated patent jurisdiction, the Communication outlines a number of actions as the keystone to maintain a high-quality industrial property rights system for the region in the 21st century.

It sets out to support inventors in making informed choices on the protection of their industrial property rights and calls for robust enforcement against counterfeiting and piracy. The Communication also intends to ensure that industrial property rights within Europe are of high quality and that they are accessible to all innovators, particularly those workin in small- and medium-sized enterprises (SMEs).

Springboard for competitiveness in the global economy

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight